Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer

Thyroid

Volumn 18, Issue 11, 2008, Pages 1165-1170

  Goldenberg, David ^a   Zagon, Ian S ^a   Fedok, Fred ^a   Crist, Henry S ^a   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; GROWTH FACTOR RECEPTOR; OPIOID GROWTH FACTOR; OPIOID GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE EXPRESSION; GOITER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; RECEPTOR BINDING; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; CARCINOMA, PAPILLARY; ENKEPHALIN, METHIONINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KINETICS; MALE; MIDDLE AGED; RECEPTORS, OPIOID; THYROID NEOPLASMS; YOUNG ADULT;

EID: 56549125157     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0112     Document Type: Article

References (48)

1. Robbins J 1991 Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 115:133-147.
2. Tuttle RM, Leboeuf R, Martorella AJ 2007 Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin N Am 36:753-778.
3. Jemal AV, Siegal R, Ward E, Murray T, Xu J, Thun MJ 2007 Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
4. Baker SR, Bhatti WA 2006 The thyroid cancer epidemic: is it the dark side of the CT revolution? Eur J Radiol 60:67-69.
5. DeGroot LJ, Kaplan EL, McCormick M, Straus FH 1990 Natural history, treatment, and course of thyroid papillary carcinoma. J Clin Endocrinol Metab 71:414-424.
6. Blankenship DR, Chin E, Terris DJ 2005 Contemporary management of thyroid cancer. Am J Otolaryngol Head Neck Med Surg 26:249-260.
7. Sarlis NJ 2000 Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects. Rev Endocr Metab Disord 1:183-196.
8. 18F-FDG-PET in the follow-up of thyroid cancer. Acta Med Austriaca 30:17-21.
9. 131I whole body scintigraphy in thyroid cancer patients. Q J Nucl Med 43:188-194.
10. Patel KN, Shaha AR 2005 Locally advanced thyroid cancer. Curr Opin Otolaryngol Head Neck Surg 13:112-116.
11. Are C, Shaha AR 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453-464.
12. Green LD, Mack L, Pasieka JL 2006 Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies. J Surg Oncol 94:725-736.
13. Bisignani GJ, McLaughlin PJ, Ordille SD, Beltz MS, Jarowenko MV, Zagon IS 1999 Human renal cell cancer proliferation in tissue culture is tonically inhibited by opioid growth factor. J Urol 162:2186-2191.
14. Zagon IS, McLaughlin PJ 1993 Opioid growth factor receptor in the developing nervous system. In: Zagon IS, McLaughlin PJ (eds) Receptors in the Developing Nervous System. Vol. 1. Growth Factors and Hormones. Chapman & Hall, London, pp 39-62.
15. 5]-enkephalin, and the etiology, pathogenesis, and treatment of gastrointestinal cancer. In: Plotnikoff NP, Faith RE, Murgo AJ, Good RA (eds) Cytokines-Stress and Immunity. CRC Press, Boca Raton, FL, pp 245-260.
16. Zagon IS, Verderame MF, McLaughlin PJ 2002 The biology of the opioid growth factor (OGFr). Brain Res Rev 38:351-376.
17. Zagon IS, Sassani JW, Malefyt KJ, McLaughlin PJ 2006 Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Arch Ophthalmol 124:1620-1624.
18. Blebea J, Mazo JE, Kihara TK, Vu J-H, McLaughlin PJ, Atnip RG, Zagon IS 2000 Opioid growth factor modulates angiogenesis. J Vasc Surg 32:364-373.
19. Zagon IS, McLaughlin PJ 2003 Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 37:79-88.
20. Zagon IS, McLaughlin PJ 2005 Opioids and differentiation in human cancer cells. Neuropeptides 39:495-505.
21. Zagon IS, Hytrek SD, McLaughlin PJ 1996 Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol 271:R511-R518.
22. Zagon IS, Smith JP, McLaughlin PJ 1999 Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 14:577-584.
23. Zagon IS, Smith JP, Conter R, McLaughlin PJ 2000 Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma. Int J Mol Med 5:77-84.
24. Zagon IS, Verderame MF, Hankins J, McLaughlin PJ 2007 Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer. Int J Oncol 30:775-783.
25. McLaughlin PJ, Levin RJ, Zagon IS 1999 Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int J Oncol 14:991-998.
26. McLaughlin PJ, Levin RJ, Zagon IS 2000 The opioid growth factor receptor in human head and neck squamous cell carcinoma. Int J Mol Med 5:191-196.
27. Zagon IS, McLaughlin PJ 2004 Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Int J Oncol 24:1443-1448.
28. McLaughlin PJ, Zagon IS 2006 Progression of squamous cell carcinoma of the head and neck is associated with downregulation of the opioid growth factor receptor (OGFr). Int J Oncol 28:1577-1583.
29. Zagon IS, Wu Y, McLaughlin PJ 1999 Opioid growth factor and organ development in rat and human embryos. Brain Res 839:313-322.
30. Zagon IS, Roesener CD, Verderame MF, Levin RJ, McLaughlin PJ 2000 Cell cycle regulation of human neoplasias by opioid growth factor (OGF). Int J Oncol 17:1053-1061.
31. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ 2007 The OGF-OGFr axis utilizes the p16 pathway to inhibit progression of human squamous cell carcinoma of the head and neck. Cancer Res 67:10511-10518.
32. Zagon IS, Ruth TB, Leure-duPree AE, Sassani JW, McLaughlin PJ 2003 Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res 967:37-47.
33. Zagon IS, Ruth TB, McLaughlin PJ 2005 Nucleocytoplasmic distribution of opioid growth factor (OGF) and its receptor (OGFr) in tongue epithelium. Anat Rec 282A:24-37.
34. 5]-enkephalin. Brain Res 849:147-154.
35. McLaughlin PJ, Stack BC, Levin RJ, Fedok F, Zagon IS 2003 Defects in the OGF receptor (OGFr) in human squamous cell carcinoma of the head and neck. Cancer 97:1701-1710.
36. Zagon IS, McLaughlin PJ 1983 Naltrexone modulates tumor response in mice with neuroblastoma. Science 221:671-673.
37. Zagon IS, Gibo DM, McLaughlin PJ 1990 Adult and developing human cerebella exhibit different profiles of opioid binding sites. Brain Res 523:62-68.
38. Zagon IS, McLaughlin PJ 1993 Production and characterization of polyclonal and monoclonal antibodies to zeta (ζ) opioid receptor. Brain Res 630:295-302.
39. 5]-enkephalin, and the zeta (ζ) opioid receptor in vertebrate cornea. Brain Res 671:105-111.
40. Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ 2008 Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med 233:968-979.
41. Ball DW 2007 Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin N Am 36:823-837.
42. Rosen H, Behar O, Abramsky O, Ovadia H 1988 Regulated expression of proenkephalin A in normal lymphocytes. J Immunol 143:3703-3707.
43. Young JB, Burgi-Saville E, Burgi U, Landsberg L 2005 Sympathetic nervous system activity in rat thyroid: potential role in goitrogenesis. Am J Physiol Endocrinol Metab 288:E861-E867.
44. Kundra P, Burman KD 2007 Thyroid cancer molecular signaling pathways and use of targeted therapy. Endocrinol Metab Clin N Am 36:839-853.
45. Xing M 2007 Gene methylation in thyroid tumorigenesis. Endocrinol 148:948-953.
46. Ciampolillo A, de Tullio C, Giorgino F 2005 The IGF-1=IGF-1 receptor pathway: implications in the pathophysiology of thyroid cancer. Curr Med Chem 12:2881-2891.
47. Baris O, Mirebeau-Prunier D, Savagner F, Rodien P, Ballester B, Loriod B, Granjeaud S, Guyetant S, Franc B, Houlgatte R, Reynier P, Malthiery Y 2005 Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma. Oncogene 24:4155-4161.
48. Smith JP, Ahmad M, Conter R, Bingaman S, Harvey H, Mauger D, Demers L, McLaughlin PJ, Stanley W, Zagon IS 2004 Treatment of advanced pancreatic cancer with opioid growth factor. Anticancer Drugs 15:203-209.